drugset / Trial / NCT05862831
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-lable, multicenter phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PM1003 in the treatment of advanced solid tumors.
Timeline
- Start
- 2021-09-07
- Primary completion
- 2025-09-07
- Completion
- 2025-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PM1003 | Monoclonal antibody | 0.02 mg/kg | Intravenous |
| Subject | PM1003 | Monoclonal antibody | 10 mg/kg | Intravenous |